Publications
Dec 1, 2024
Promoting Quality Care and Reliable Research with Ethiqa XR
Ethiqa XR provides captive rodents, ferrets, laboratory rabbits, and non-human primates with a high standard of post-procedural pain control. Supported by proven research and practical experience, the product helps veterinary teams and institutions achieve scientific goals while ensuring compassionate care for every animal.
Proven Relief Backed by Science
Ethiqa XR offers pain relief for up to 72 hours supported by peer-reviewed studies, giving veterinary teams confidence in care and research outcomes.
Built for Laboratory Environments
Formulated specifically for the unique demands of laboratory animal medicine.
Trusted by Veterinary Experts
Leading laboratory veterinarians rely on Ethiqa XR to help control post-procedural pain without compromising study integrity or regulatory standards.
A Commitment to Welfare
Ethiqa XR lasts up to 72 hours helping advance animal welfare by minimizing the handling of the animal which reduces stress for both animals and staff. It provides reliable and precise dosing ensuring safe and consistent treatment.
Delivering an Effective Solution for Pain Management
Ethiqa XR provides a sustained-release buprenorphine formulation designed for effective, single-dose treatment for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates.
The product is rooted in science, proven through research, and supported by direct veterinary expertise ensuring you have the tools and confidence to deliver exceptional care.
- Up to 72 hours of continuous pain relief from a single dose
- Demonstrated safety across multiple species and research settings
- Backed by peer-reviewed data and regulatory compliance guidance
What Sets Ethiqa XR Apart
Delivering precise, long-lasting pain management for captive rodents, ferrets, laboratory rabbits, and non-human primates, Ethiqa XR combines proven efficacy with practical reliability. Backed by research and real-world experience, it supports both scientific goals and compassionate care. Designed for ease of use and regulatory compliance, it gives veterinary teams confidence in every procedure.
Trusted by Experts
Our product is recommended by experienced laboratory veterinarians for its reliability, safety, and effectiveness in research settings.
Proven Through Research
Backed by peer-reviewed studies, Ethiqa XR delivers measurable results you can depend on for consistent, compliant control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates.
Dedicated to Compliance
Ethiqa XR meets and maintains all regulatory standards while providing the highest quality of animal care.
Designed for Welfare
Every aspect of Ethiqa XR is developed to control post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates while meeting the demands of animal care.
0:00
Partnering for Care
Exceptional animal care begins with support. Veterinary teams and research facilities benefit from Ethiqa XR’s continuous support, expert guidance, and educational resources designed to address the unique challenges of laboratory animal medicine.
- Direct access to experienced veterinary experts
- Practical resources and educational tools for your team
- Ongoing support tailored to your research needs
Stay Informed with the Latest Research and Insights
We’re Here to Support You
Your insights matter—because animal care starts with true collaboration. Ethiqa XR is a trusted, science-backed product for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. We are here to support you every step of the way. Connect with our team, ask questions, and stay informed. Together, we’re advancing animal welfare and raising the standard of care.
Contact Us
Real people providing dedicated support
Direct access to experienced veterinary experts
Backed by rigorous, proven research data
ETH.LP.210.01.D.ALL.AL
Boxed Warning
Abuse Potential
ETHIQA XR contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ETHIQA XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g., depression).
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ETHIQA XR. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.
Accidental Exposure
Because of the potential for adverse reactions associated with accidental exposure, ETHIQA XR should only be administered by veterinarians, veterinary technicians, or laboratory staff who are trained in the handling of potent opioids. Accidental exposure to ETHIQA XR, especially in children, can result in a fatal overdose of buprenorphine.
Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants
Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
See HUMAN SAFETY WARNINGS for detailed information.
Important Safety Information
For Captive Rodents, Ferrets, Laboratory Rabbits, and Non-Human Primates:
Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.
Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiqa XR have been administered concomitantly in mice.
Do not house rats on wood chip-type bedding after administration of Ethiqa XR. Pica involving wood chip type bedding can be lethal.
Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR.
The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.
For Humans:
Not for use in humans. Keep out of reach of children and pets.
Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.
Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.
Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.
For more information, consult the Prescribing Information including the Boxed Warning.
SA.EthiqaXR.060.05.2024